Literature DB >> 23733782

Minimal residual disease in multiple myeloma.

Nikhil C Munshi, Kenneth C Anderson.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 23733782      PMCID： PMC5321086          DOI： 10.1200/JCO.2013.49.2124

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  27 in total

1.  Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma.

Authors:  G Martinelli; C Terragna; E Zamagni; S Ronconi; P Tosi; R M Lemoli; G Bandini; M R Motta; N Testoni; M Amabile; E Ottaviani; N Vianelli; A de Vivo; A Gozzetti; S Tura; M Cavo
Journal:  J Clin Oncol       Date:  2000-06       Impact factor: 44.544

Review 2.  Multiple myeloma.

Authors:  Antonio Palumbo; Kenneth Anderson
Journal:  N Engl J Med       Date:  2011-03-17       Impact factor: 91.245

3.  Real-Time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma.

Authors:  M Ladetto; J W Donovan; S Harig; A Trojan; C Poor; R Schlossnan; K C Anderson; J G Gribben
Journal:  Biol Blood Marrow Transplant       Date:  2000       Impact factor: 5.742

Review 4.  Latest advances and current challenges in the treatment of multiple myeloma.

Authors:  Anuj Mahindra; Jacob Laubach; Noopur Raje; Nikhil Munshi; Paul G Richardson; Kenneth Anderson
Journal:  Nat Rev Clin Oncol       Date:  2012-02-21       Impact factor: 66.675

Review 5.  Current and future imaging modalities for multiple myeloma and its precursor states.

Authors:  Esther Tan; Brendan M Weiss; Esther Mena; Neha Korde; Peter L Choyke; Ola Landgren
Journal:  Leuk Lymphoma       Date:  2011-06-08

6.  Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation.

Authors:  Sara Galimberti; Edoardo Benedetti; Fortunato Morabito; Federico Papineschi; Vincenzo Callea; Rita Fazzi; Caterina Stelitano; Francesca Andreazzoli; Francesca Guerrini; Elena Ciabatti; Massimo Martino; Francesco Nobile; Pasquale Iacopino; Mario Petrini
Journal:  Leuk Res       Date:  2005-08       Impact factor: 3.156

7.  Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma.

Authors:  Bruno Paiva; Joaquin Martinez-Lopez; Maria-Belen Vidriales; Maria-Victoria Mateos; Maria-Angeles Montalban; Elena Fernandez-Redondo; Lourdes Alonso; Albert Oriol; Ana-Isabel Teruel; Raquel de Paz; José-Garcia Laraña; Enrique Bengoechea; Alejandro Martin; Joaquin Diaz Mediavilla; Luis Palomera; Felipe de Arriba; Joan Bladé; Alberto Orfao; Juan-Jose Lahuerta; Jesus F San Miguel
Journal:  J Clin Oncol       Date:  2011-03-14       Impact factor: 44.544

8.  F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma.

Authors:  Twyla B Bartel; Jeff Haessler; Tracy L Y Brown; John D Shaughnessy; Frits van Rhee; Elias Anaissie; Terri Alpe; Edgardo Angtuaco; Ronald Walker; Joshua Epstein; John Crowley; Bart Barlogie
Journal:  Blood       Date:  2009-05-14       Impact factor: 22.113

9.  Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients.

Authors:  Bruno Paiva; Maria-Belén Vidriales; Jose J Pérez; Gema Mateo; Maria Angeles Montalbán; Maria Victoria Mateos; Joan Bladé; Juan José Lahuerta; Alberto Orfao; Jesús F San Miguel
Journal:  Haematologica       Date:  2009-11       Impact factor: 9.941

10.  Lenalidomide after stem-cell transplantation for multiple myeloma.

Authors:  Philip L McCarthy; Kouros Owzar; Craig C Hofmeister; David D Hurd; Hani Hassoun; Paul G Richardson; Sergio Giralt; Edward A Stadtmauer; Daniel J Weisdorf; Ravi Vij; Jan S Moreb; Natalie Scott Callander; Koen Van Besien; Teresa Gentile; Luis Isola; Richard T Maziarz; Don A Gabriel; Asad Bashey; Heather Landau; Thomas Martin; Muzaffar H Qazilbash; Denise Levitan; Brian McClune; Robert Schlossman; Vera Hars; John Postiglione; Chen Jiang; Elizabeth Bennett; Susan Barry; Linda Bressler; Michael Kelly; Michele Seiler; Cara Rosenbaum; Parameswaran Hari; Marcelo C Pasquini; Mary M Horowitz; Thomas C Shea; Steven M Devine; Kenneth C Anderson; Charles Linker
Journal:  N Engl J Med       Date:  2012-05-10       Impact factor: 91.245
View more
  19 in total

1.  Copper 64-labeled daratumumab as a PET/CT imaging tracer for multiple myeloma.

Authors:  Enrico Caserta; Junie Chea; Megan Minnix; Erasmus K Poku; Domenico Viola; Steven Vonderfecht; Paul Yazaki; Desiree Crow; Jihane Khalife; James F Sanchez; Joycelynne M Palmer; Susanta Hui; Nadia Carlesso; Jonathan Keats; Young Kim; Ralf Buettner; Guido Marcucci; Steven Rosen; John Shively; David Colcher; Amrita Krishnan; Flavia Pichiorri
Journal:  Blood       Date:  2018-01-04       Impact factor: 22.113

Review 2.  European perspective on multiple myeloma treatment strategies in 2014.

Authors:  Heinz Ludwig; Pieter Sonneveld; Faith Davies; Joan Bladé; Mario Boccadoro; Michele Cavo; Gareth Morgan; Javier de la Rubia; Michel Delforge; Meletios Dimopoulos; Hermann Einsele; Thierry Facon; Hartmut Goldschmidt; Philippe Moreau; Hareth Nahi; Torben Plesner; Jesús San-Miguel; Roman Hajek; Pia Sondergeld; Antonio Palumbo
Journal:  Oncologist       Date:  2014-07-25

Review 3.  Consolidation and maintenance therapy for multiple myeloma after autologous transplantation: where do we stand?

Authors:  M Mohty; P G Richardson; P L McCarthy; M Attal
Journal:  Bone Marrow Transplant       Date:  2015-04-20       Impact factor: 5.483

Review 4.  Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma.

Authors:  Timothy R Rosean; Van S Tompkins; Guido Tricot; Carol J Holman; Alicia K Olivier; Fenghuang Zhan; Siegfried Janz
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

Review 5.  Identify multiple myeloma stem cells: Utopia?

Authors:  Ilaria Saltarella; Aurelia Lamanuzzi; Antonia Reale; Angelo Vacca; Roberto Ria
Journal:  World J Stem Cells       Date:  2015-01-26       Impact factor: 5.326

6.  Should minimal residual disease negativity not be the end point of myeloma therapy?

Authors:  Pieter Sonneveld
Journal:  Blood Adv       Date:  2017-03-14

Review 7.  Multiple Myeloma: Treatment is Getting Individualized.

Authors:  M B Agarwal
Journal:  Indian J Hematol Blood Transfus       Date:  2015-07-26       Impact factor: 0.900

Review 8.  Dilemmas in treating smoldering multiple myeloma.

Authors:  Inhye E Ahn; Sham Mailankody; Neha Korde; Ola Landgren
Journal:  J Clin Oncol       Date:  2014-11-24       Impact factor: 44.544

9.  Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality.

Authors:  Joaquín Martínez-López; Bruno Paiva; Lucía López-Anglada; María-Victoria Mateos; Teresa Cedena; María-Belén Vidríales; María Auxiliadora Sáez-Gómez; Teresa Contreras; Albert Oriol; Inmaculada Rapado; Ana-Isabel Teruel; Lourdes Cordón; María Jesús Blanchard; Enrique Bengoechea; Luis Palomera; Felipe de Arriba; Cecilia Cueto-Felgueroso; Alberto Orfao; Joan Bladé; Jesús F San Miguel; Juan José Lahuerta
Journal:  Blood       Date:  2015-06-18       Impact factor: 22.113

Review 10.  Back to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation.

Authors:  Christopher S Hourigan; Philip McCarthy; Marcos de Lima
Journal:  Biol Blood Marrow Transplant       Date:  2013-11-27       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.